Rakesh Jain
From Wikipedia, the free encyclopedia
Dr. Rakesh K. Jain is the Andrew Werk Cook Professor of Tumor Biology at Massachusetts General Hospital in the Harvard Medical School. Dr. Jain primarily researches tumor pathophysiology. His work on cancer therapies led to discovery of an alternate use of Herceptin, an anti-tumor cell pharmaceutical compound produced by Genentech, as an inhibitor for blood vessel growth necessary for tumor growth.[1] His award-winning work on tumor biology has been recognized by a number of professional recognitions, including the following awards in 2006:
- Distinguished Service Award, Nature Biotechnology-Miami Symposium on Angiogenesis
- Outstanding Achievement Award, Society of American Asian Scientists in Cancer Research
- Robert L. Krigel Lecture, Fox Chase Cancer Center, Philadelphia
- Alpha Chi Sigma Research Award, American Institute of Chemical Engineers
- Benjamin Zweifach Distinguished Lecture, The City College, New York
Dr. Jain received his B.Tech. degree from the Indian Institutes of Technology in Chemical Engineering in 1972 and received his M.Ch.E. and Ph.D. in Chemical Engineering from the University of Delaware in 1974 and 1976, respectively.
[edit] References
- ^ Study Said to Show Added Benefit of Genentech Breast Cancer Drug. Andrew Pollack. New York Times. Retrieved January 17, 2007.
[edit] External links
- Curriculum Vitae at Harvard Medical School
 |
This biographical article about a scientist is a stub. You can help Wikipedia by expanding it. |
